Matrix metalloproteinase-9, -10, and tissue inhibitor of matrix metalloproteinases-1 blood levels as biomarkers of severity and mortality in sepsis

IntroductionMatrix metalloproteinases (MMPs) play a role in infectious diseases through extracellular matrix (ECM) degradation, which favors the migration of immune cells from the bloodstream to sites of inflammation. Although higher levels of MMP-9 and tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) have been found in small series of patients with sepsis, MMP-10 levels have not been studied in this setting. The objective of this study was to determine the predictive value of MMP-9, MMP-10, and TIMP-1 on clinical severity and mortality in a large series of patients with severe sepsis.MethodsThis was a multicenter, observational, and prospective study carried out in six Spanish Intensive Care Units. We included 192 (125 surviving and 67 nonsurviving) patients with severe sepsis and 50 age- and sex-matched healthy controls in the study. Serum levels of MMP-9, MMP-10, TIMP-1, tumor necrosis factor (TNF)-alpha, and interleukin (IL)-10 were measured in patients with severe sepsis at the time of diagnosis and in healthy controls.ResultsSepsis patients had higher levels of MMP-10 and TIMP-1, higher MMP-10/TIMP-1 ratios, and lower MMP-9/TIMP-1 ratios than did healthy controls (P < 0.001). An association was found between MMP-9, MMP-10, TIMP-1, and MMP-9/TIMP-1 ratios and parameters of sepsis severity, assessed by the SOFA score, the APACHE-II score, lactic acid, platelet count, and markers of coagulopathy. Nonsurviving sepsis patients had lower levels of MMP-9 (P = 0.037), higher levels of TIMP-1 (P < 0.001), lower MMP-9/TIMP-1 ratio (P = 0.003), higher levels of IL-10 (P < 0.001), and lower TNF-α/IL-10 ratio than did surviving patients. An association was found between MMP-9, MMP-10, and TIMP-1 levels, and TNF-α and IL-10 levels. The risk of death in sepsis patients with TIMP-1 values greater than 531 ng/ml was 80% higher than that in patients with lower values (RR = 1.80; 95% CI = 1.13 to 2.87;P = 0.01; sensitivity = 0.73; specificity = 0.45).ConclusionsThe novel findings of our study on patients with severe sepsis (to our knowledge, the largest series reporting data about MMP levels in sepsis) are that reduced MMP-9/TIMP-1 ratios and increased MMP-10 levels may be of great pathophysiologic significance in terms of severity and mortality, and that TIMP-1 levels may represent a biomarker to predict the clinical outcome of patients with sepsis.

[1]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[2]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[3]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[4]  M. Borggrefe,et al.  Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: Prognostic value of TIMP-1 in severe sepsis , 2006, Scandinavian journal of infectious diseases.

[5]  Ta-Liang Chen,et al.  Expression of matrix metalloproteinase‐9 in human platelets: regulation of platelet activation in in vitro and in vivo studies , 2004, British journal of pharmacology.

[6]  J. Paramo,et al.  Independent association of matrix metalloproteinase‐10, cardiovascular risk factors and subclinical atherosclerosis , 2007, Journal of thrombosis and haemostasis : JTH.

[7]  S. Shapiro,et al.  Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. , 2000, The Journal of biological chemistry.

[8]  H. Lijnen.  Matrix Metalloproteinases and Cellular Fibrinolytic Activity , 2004, Biochemistry (Moscow).

[9]  P. Libby,et al.  Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. , 1998, Journal of immunology.

[10]  K. Goddard,et al.  Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. , 2005, Journal of Vascular Surgery.

[11]  J. Vincent,et al.  Blood lactate levels are better prognostic indicators than TNF and IL-6 levels in patients with septic shock , 1996, Intensive Care Medicine.

[12]  C. Libert,et al.  Matrix Metalloproteinases as Drug Targets in Infections Caused by Gram-Negative Bacteria and in Septic Shock , 2009, Clinical Microbiology Reviews.

[13]  K. Iida,et al.  Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. , 1997, American journal of respiratory and critical care medicine.

[14]  D. Brenner,et al.  Prolonged activation of jun and collagenase genes by tumour necrosis factor-α , 1989, Nature.

[15]  A. H. Drummond,et al.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases. , 1994, Nature.

[16]  L. Wahl,et al.  Inhibition of phospholipase activity in human monocytes by IFN-gamma blocks endogenous prostaglandin E2-dependent collagenase production. , 1990, Journal of immunology.

[17]  Jason Phua,et al.  LACTATE, PROCALCITONIN, AND AMINO-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE VERSUS CYTOKINE MEASUREMENTS AND CLINICAL SEVERITY SCORES FOR PROGNOSTICATION IN SEPTIC SHOCK , 2008, Shock.

[18]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[19]  C. Esmon.  Interactions between the innate immune and blood coagulation systems , 2004, Trends in Immunology.

[20]  N. Webster,et al.  Matrix metalloproteinase‐9 concentrations in critically ill patients , 2001, Anaesthesia.

[21]  C. Liang,et al.  Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. , 1999, American journal of respiratory cell and molecular biology.

[22]  S. Weiss,et al.  Role of stromelysin 1 and gelatinase B in experimental acute lung injury. , 2001, American journal of respiratory cell and molecular biology.

[23]  J. Michel,et al.  Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. , 2001, Cardiovascular Research.

[24]  P. Jurasz,et al.  Role of metalloproteinases in platelet function. , 2008, Thrombosis research.

[25]  E. Waubant,et al.  T cell gelatinases mediate basement membrane transmigration in vitro. , 1995, Journal of immunology.

[26]  W. Stetler-Stevenson,et al.  Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. , 1992, The Journal of biological chemistry.

[27]  J. Sheu,et al.  Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation. , 2006, European journal of pharmacology.

[28]  S. Landas,et al.  Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. , 2003, The Journal of surgical research.

[29]  P. Libby,et al.  Generation of Biologically Active IL-1β by Matrix Metalloproteinases: A Novel Caspase-1-Independent Pathway of IL-1β Processing , 1998, The Journal of Immunology.

[30]  Alain Cariou,et al.  Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] , 2004, Critical care.

[31]  P. Suter,et al.  Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. , 1996, American journal of respiratory and critical care medicine.

[32]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.

[33]  C. Vlachopoulos,et al.  Divergent associations of tissue inhibitors of metalloproteinases-1 and -2 with the prothrombotic/fibrinolytic state. , 2007, Atherosclerosis.

[34]  C. Kluft.  The Fibrinolytic System and Thrombotic Tendency , 2003, Pathophysiology of Haemostasis and Thrombosis.

[35]  S. Maitra,et al.  Inhibition of Matrix Metalloproteinases by Chemically Modified Tetracyclines in Sepsis , 2003, Shock.

[36]  J. Friedland,et al.  The paradox of matrix metalloproteinases in infectious disease , 2005, Clinical and experimental immunology.

[37]  D. Mennerich,et al.  Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response , 2005, Journal of inflammation.

[38]  C. Sprung,et al.  Sepsis in European intensive care units: Results of the SOAP study* , 2006, Critical care medicine.

[39]  G. Opdenakker,et al.  Gelatinase B deficiency protects against endotoxin shock , 2002, European journal of immunology.

[40]  E. Amento,et al.  Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. , 1991, The Journal of clinical investigation.

[41]  P. Libby,et al.  C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. , 2006, Journal of the American College of Cardiology.

[42]  Constance E. Brinckerhoff,et al.  Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.

[43]  A. Ager,et al.  Transendothelial migration of lymphocytes across high endothelial venules into lymph nodes is affected by metalloproteinases. , 2001, Blood.

[44]  W. Stetler-Stevenson,et al.  Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. , 1994, The Journal of biological chemistry.

[45]  B. Mecham,et al.  Individual Matrix Metalloproteinases Control Distinct Transcriptional Responses in Airway Epithelial Cells Infected with Pseudomonas aeruginosa , 2007, Infection and Immunity.

[46]  T. Nakamura,et al.  Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: effect of fiber-immobilized polymyxin B treatment. , 1998, The American journal of the medical sciences.

[47]  A. Sollevi,et al.  Differential release of matrix metalloproteinase‐9 and nitric oxide following infusion of endotoxin to human volunteers , 2003, Acta anaesthesiologica Scandinavica.

[48]  Arthur S Slutsky,et al.  Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—A review , 2006, Critical care medicine.